Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30900
Title: Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
Austin Authors: DiIorio, Michael;Kennedy, Kevin;Liew, Jean W;Putman, Michael S;Sirotich, Emily;Sattui, Sebastian E;Foster, Gary;Harrison, Carly;Larché, Maggie J;Levine, Mitchell;Moni, Tarin T;Thabane, Lehana;Bhana, Suleman;Costello, Wendy;Grainger, Rebecca;Machado, Pedro M;Robinson, Philip C;Sufka, Paul;Wallace, Zachary S;Yazdany, Jinoos;Gore-Massy, Monique;Howard, Richard A;Kodhek, More A;Lalonde, Nadine;Tomasella, Laura-Ann;Wallace, John;Akpabio, Akpabio;Alpízar-Rodríguez, Deshiré;Beesley, Richard P;Berenbaum, Francis;Bulina, Inita;Chock, Eugenia Yupei;Conway, Richard;Duarte-García, Alí;Duff, Eimear;Gheita, Tamer A;Graef, Elizabeth R;Hsieh, Evelyn;El Kibbi, Lina;Liew, David F L ;Lo, Chieh;Nudel, Michal;Singh, Aman Dev;Singh, Jasvinder A;Singh, Namrata;Ugarte-Gil, Manuel F;Hausmann, Jonathan S;Simard, Julia F;Sparks, Jeffrey A
Affiliation: Department of Medicine, Clinical Epidemiology Unit, Sweden..
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Medicine, Harvard Medical School, Boston, Massachusetts, USA
Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA
Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA
Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
LupusChat, New York, New York, USA
Rheumatology, Crystal Run Healthcare, Middletown, New York, USA
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA jsparks@bwh.harvard.edu.. Medicine, Harvard Medical School, Boston, Massachusetts, USA
Rheumatology, Autoinflammatory UK, Edinburgh, UK
Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia
Metro North Hospital & Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia
Rheumatology
Clinical Pharmacology and Therapeutics
MRC Centre for Neuromuscular Diseases, University College London, London, UK
Rheumatology, University College London Centre for Rheumatology, London, UK
Juvenile Arthritis Research, European Network for Childhood Arthritis (ENCA), Tonbridge, UK
Rheumatology, HealthPartners, St Paul, Minnesota, USA
Clinical Epidemiology Program and Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA
Medicine/Rheumatology, University of California, San Francisco, California, USA
Lupus Foundation of America Inc, Washington, District of Columbia, USA
Spondylitis Association of America, Van Nuys, California, USA
Section of Rheumatology, Yale School of Medicine, New Haven, Connecticut, USA
Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA
Rheumatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Division of Rheumatology, Yale School of Medicine, New Haven, Connecticut, USA
Rheumatology, VA Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut, USA
Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
Medicine Service, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA
Medicine, Division of Rheumatology, University of Washington, Seattle, Washington, USA
Rheumatology, Boston Children's Hospital, Boston, Massachusetts, USA
Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Epidemiology and Population Health and Department of Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, California, USA
Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada..
Medicine, McMaster University, Hamilton, Ontario, Canada..
Department of Health Research Methods, Evidence and Impact (HEI); Medicine, McMaster University, Hamilton, Ontario, Canada..
Divisions of Clinical Immunology and Allergy/Rheumatology, McMaster University Department of Medicine, Hamilton, Ontario, Canada..
Department of Health Research Methods, Evidence and Impact (HEI), McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada..
Department of Biochemistry & Biomedical Sciences, McMaster University Faculty of Science, Hamilton, Ontario, Canada..
Department of Health Research Methods, Evidence and Impact (HEI), McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada..
N/A, Irish Children's Arthritis Network (iCAN), Tipperary, Ireland..
Department of Medicine, University of Otago Wellington, Wellington, New Zealand..
Lupus Foundation of Kenya, Nairobi, Kenya..
Patient Board, Covid-19 Global Rheumatology Alliance, London, Ontario, Canada..
Arthritis Kids South Africa, Johannesburg, South Africa..
Internal Medicine, University of Uyo Teaching Hospital, Uyo, Nigeria..
Research Unit, Mexican College of Rheumatology, Coyoacan, Mexico..
Rheumatology, Sorbonne Université, Paris, France..
Rheumatology, Paul Stradins Clinical University Hospital, Riga, Latvia..
Department of Rheumatology, Saint James's Hospital, Dublin, Ireland..
Rheumatology, Saint James's Hospital, Dublin, Ireland..
Rheumatology and Clinical Immunology, Faculty of Medicine, Cairo University, Cairo, Egypt..
Internal Medicine Department, Division of Rheumatology, Specialized Medical Center Hospital, Riyadh, Saudi Arabia..
Rheumatology, I-Shou University College of Medicine, Yanchau Sheng, Taiwan..
N/A, The Israeli Association for RMDs patients "Mifrakim Tz'eirim", Haifa, Israel..
Department of Community Medicine, Government Medical College Amritsar, Amritsar, Punjab, India.. Rajindra Hospital Patiala, Patiala, Punjab, India..
School of Medicine, Universidad Cientifica del Sur, Lima, Peru.. Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru..
Issue Date: Sep-2022
Publication information: RMD open 2022; 8(2): e002587
Abstract: We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021-15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30900
DOI: 10.1136/rmdopen-2022-002587
ORCID: http://orcid.org/0000-0001-8230-091X
http://orcid.org/0000-0001-9699-4000
http://orcid.org/0000-0002-7087-8543
http://orcid.org/0000-0002-3945-6828
http://orcid.org/0000-0002-8411-7972
http://orcid.org/0000-0002-3156-3418
http://orcid.org/0000-0002-4920-6494
http://orcid.org/0000-0002-6930-0517
http://orcid.org/0000-0001-8252-7815
http://orcid.org/0000-0003-1679-9745
http://orcid.org/0000-0001-8451-8883
http://orcid.org/0000-0003-3485-0006
http://orcid.org/0000-0003-1728-1999
http://orcid.org/0000-0003-0786-8788
http://orcid.org/0000-0001-5735-9856
http://orcid.org/0000-0002-5556-4618
Journal: RMD open
PubMed URL: 36104117
Type: Journal Article
Subjects: COVID-19
inflammation
patient reported outcome measures
vaccination
Appears in Collections:Journal articles

Show full item record

Page view(s)

52
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.